Nephrogenic Systemic Fibrosis Lawyers are No Longer Reviewing New Cases.
Nephrogenic Systemic Fibrosis (NFS) is a progressive disorder which could occur in those with chronic kidney problems or impaired renal function. It is associated with scarring of the skin and connective tissue throughout the body, known as fibrosis. The skin thickens and becomes hard, rigid and coarse, which severely restricts movement of the joints. It can also lead to widespread fibrosis of other organs and in some cases it is fatal.
The development of NSF has been directly tied to the use of gadolinium contrast injections which are given during an MRI and MRA to assist the physicians in differentiating blood vessels from nearby tissue.
The product liability lawyers at Saiontz & Kirk, P.A. previously pursued a Nephrogenic Systemic Fibrosis settlement from the manufacturers of gadolinium contrasts for failing to properly research their product or warn of these risks. New cases are no longer being pursued. This page is provided for informational purposes to outline a prior case investigated by our law firm.
Nephrogenic Systemic Fibrosis (NSF) is a chronic, progressive condition. Previously referred to as Nephrogenic Fibrosing Dermopathy (NFD), the disease was first identified in 1997. There are over 400 reported cases of Nephrogenic Systemic Fibrosis worldwide, but most experts expect that number to increase as physicians become more aware of the condition.
The disorder results in an increase of collagen in the tissues, causing thick and hard skin, which is often described as “woody” and “shiny”. It is painful and often causes restricted mobility of the joints. In many cases, individuals diagnosed with nephrogenic systemic fibrosis become dependent on a wheelchair within a few weeks of the disease onset. It can also impact other internal organs, such as the lungs, heart, diaphragm, esophagus, skeletal muscle and other tissues.
>>INFORMATION: Nephrogenic Systemic Fibrosis Symptoms
Nearly all of the individuals diagnosed with NSF received a gadolinium based contrast for magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA) between two days and 18 months before the onset of problems. The disorder is not well understood, and NSF research is continuing to obtain better information about how gadolinium contrasts cause the condition. There are currently no NSF treatments which are consistently effective, but some therapies have lead to improvement for some sufferers.
In 2006, researchers confirmed that there is a direct link between the MRI gadolinium contrast and the development of Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD). Based on reported cases currently available, it appears that about 5% of those with kidney failure or kidney problems experience the systemic disorder after receiving a gadolinium agent.
>>INFORMATION: Nephrogenic Systemic Fibrosis lawsuits